Literature DB >> 2694342

Absorption, distribution, metabolism, and excretion of furazolidone. A review of the literature.

A H White1.   

Abstract

Systematic determination of profiles of absorption, distribution, metabolism, and excretion of drugs is standard in the pharmaceutical industry today, and powerful, precise, and specific analytical methods are available to carry out such studies. In the case of furazolidone, developed in the late 1940s, the data were obtained with less precise analytical procedures. This gave rise to the misconception that furazolidone is poorly absorbed and inactivated in the intestine. Newer techniques, such as chromatography and 14C studies, have helped to establish that the drug is indeed well absorbed. Levels of radiolabeled analyte measured in urine indicate that more than 65% of an oral dose is recovered in each animal species tested. Chromatographic methods indicate that little or no intact drug is recovered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694342     DOI: 10.3109/00365528909091325

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

1.  Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone.

Authors:  D Dionisio; L I Manneschi; S Di Lollo; A Orsi; G Sterrantino; M Meli; M Gabbrielli; A Tani; A Papucci; F Leoncini
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

2.  In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis.

Authors:  E M Narcisi; W E Secor
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; J L Zhang
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.

Authors:  S A Calafatti; R A Ortiz; M Deguer; M Martinez; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

5.  Persistent damage to Enterocytozoon bieneusi, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients.

Authors:  D Dionisio; L I Manneschi; S Di Lollo; A Orsi; G Sterrantino; F Leoncini; M Pozzi; M A Vinattieri; A Tani; A Papucci
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

6.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

7.  Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.

Authors:  Jaime N Eisig; Fernando M Silva; Ricardo C Barbuti; Tomás Navarro Rodriguez; Peter Malfertheiner; Joaquim P P Moraes Filho; Schlioma Zaterka
Journal:  BMC Gastroenterol       Date:  2009-05-26       Impact factor: 3.067

8.  Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection.

Authors:  Airu Liu; Yuxin Wang; Yingxiao Song; Yiqi Du
Journal:  Saudi J Gastroenterol       Date:  2020 Mar-Apr       Impact factor: 2.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.